DnB Asset Management AS Purchases 1,255 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

DnB Asset Management AS increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 21.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,067 shares of the company’s stock after purchasing an additional 1,255 shares during the period. DnB Asset Management AS’s holdings in Vaxcyte were worth $579,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PCVX. Whipplewood Advisors LLC bought a new stake in Vaxcyte in the 4th quarter valued at $28,000. Smartleaf Asset Management LLC increased its stake in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after acquiring an additional 260 shares during the period. Blue Trust Inc. raised its position in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after purchasing an additional 371 shares in the last quarter. Assetmark Inc. raised its position in Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after purchasing an additional 775 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. bought a new position in Vaxcyte during the third quarter worth about $92,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Vaxcyte

In related news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at approximately $9,472,066.41. The trade was a 6.81 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,250 shares of company stock valued at $3,170,738 in the last quarter. 3.10% of the stock is currently owned by insiders.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX opened at $33.69 on Thursday. Vaxcyte, Inc. has a 52-week low of $30.12 and a 52-week high of $121.06. The company has a market capitalization of $4.34 billion, a P/E ratio of -7.32 and a beta of 1.02. The company has a 50-day simple moving average of $76.94 and a 200 day simple moving average of $90.84.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. As a group, equities analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on PCVX shares. The Goldman Sachs Group dropped their target price on Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a report on Tuesday. Bank of America reduced their target price on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a research note on Tuesday. Guggenheim reiterated a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Finally, Needham & Company LLC decreased their price objective on shares of Vaxcyte from $140.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte has a consensus rating of “Buy” and a consensus target price of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.